Skip to main content

Table 2 Diagnostic accuracy of ten ACPAs (presented in alphabetical order), anti-CCP2 antibodies, anti-CarP antibodies and RF isotypes, analysed separately and in combination with the three RF isotypes, for RA development in pre-symptomatic individuals

From: Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis

Antibody Sensitivity (95 % CI) Odds ratio (95 % CI) + IgA-RF OR (95 % CI)a + IgG-RF OR (95 % CI)a + IgM-RF OR (95 % CI)a
CCP-2 29.6 (26.08–33.39) 20.26 (10.58–38.83) 50.7 (12.4–207.5) 30.2 (7.3–124.9) 67.6 (16.6–275.9)
CEP-1 23.9 (20.64–27.51) 4.75 (3.14–7.2) 19.6 (7.1–54.4) 13.3 (4.7–37.3) 48.1 (11.7–197.4)
CitC1III 12.71 (10.26–15.66) 3.77 (2.22–6.4) 36.9 (5.0–271.5)b 25.1 (3.4–186.9) 45.7 (6.3–333.6)
Fibα563–583 7.63 (5.74–10.08) 1.65 (0.99–2.78) 21.7 (2.9–162) 11.8 (1.5–91.7) 13.9 (3.3–59.2)
Fibα580–600 6.95 (5.16–9.32) 1.05 (0.65–1.7) 6.2 (1.8–21.5) 6.3 (1.8–21.7) 5.2 (1.5–18.3)
Fibβ36–52 22.54 (19.36–26.1) 3.98 (2.66–5.95) 17.5 (6.3–48.6) 15 (4.6–49) 45.2 (11–185.7)
Fibβ62–81a 8.64 (6.63–11.22) 2.77 (1.56–4.92) 17.5 (2.3–131.4) 9.1 (1.1–72.8) 18.1 (2.4–135.8)
Fibβ62–81b 13.39 (10.88–16.4) 9.2 (4.4–19.24) 42.6 (5.8–311.7)b 24.8 (3.3–183.9)b 50.2 (6.9–366.2)b
Filaggrin 21.86 (18.72–25.39) 9.39 (5.33–16.55) 22.9 (7.1–73.6) 48.4 (6.6–353.4) 37.9 (9.2–156)
Vim2–17 5.59 (4–7.79) 1.31 (0.75–2.29) 7.6 (1.7–33.5) 10.1 (1.3–79.6) 13.6 (1.8–104.3)
Vim60–75 9.49 (7.38–12.15) 1.93 (1.18–3.14) 8.1 (2.4–27.3) 9.1 (2.1–39.5) 9.3 (2.8–30.8)
CarP 13.78 (10.81–17.43) 5.83 (2.08–16.36) 12.9 (1.7–95.7)b 10.6 (1.4–78.6) 16.2 (2.2–119.2)b
IgA-RF 24.75 (21.46–28.37) 9.07 (5.5–14.96)a – 23.9 (7.4–76.7) 21.9 (8.8–54.6)
IgG-RF 17.56 (14.72–20.83) 5.89 (3.53–9.82)a 23.9 (7.4–76.7) – 34.5 (8.4–142.2)
IgM-RF 26.09 (22.73–29.76) 11.08 (6.64–18.5)a 21.9 (8.8–54.6) 34.5 (8.4–142.2) –
  1. ACPA anti-citrullinated protein antibodies, anti-CarP antibodies against carbamylated proteins, anti-CCP anti-cyclic citrullinated peptide antibodies, CEP-1 α-enolase, CI confidence interval, Fib fibrinogen, IgA immunoglobulin A, IgG immunoglobulin G, IgM immunoglobulin M, RF rheumatoid factor, Vim vimentin
  2. Data represent pre-symptomatic individuals with 598 samples. Logistic regression analysis was performed with the combinations using two groups (++ vs. all other combinations).
  3. aCalculation adjusted for age at the time of sampling
  4. bCalculations made with a hypothetical control individual double positive for the respective antibodies
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us